[ORGANIZATION]
Sail Biomedicines
Featured in 1 tracked story · first seen
Also covered in
-
Johnson & Johnson secures $2.58 bn option to acquire in‑vivo CAR‑T developer Sail Biomedicines
[BUSINESS] · 2 sources ·
[ORGANIZATION]
Featured in 1 tracked story · first seen
[BUSINESS] · 2 sources ·